US Markets for Interventional Cardiology Exceed $4 billion

July 27, 2005—An aging baby boomer population at increased risk for coronary artery disease (CAD) is driving US demand for less invasive techniques to treat adverse cardiovascular conditions. Rising procedure volumes in the US have made interventional cardiology (IC), the minimally invasive medical specialty concerned with the treatment of CAD, a burgeoning and lucrative market. According to a new report published by Millennium Research Group (MRG), over 1 million Americans underwent a percutaneous coronary intervention (PCI) procedure in 2004, contributing partly to IC market revenue in excess of $4 billion.

The US IC market, comprising coronary stents, percutaneous transluminal coronary angioplasty (PTCA) balloons, accessory devices (PTCA guidewires, diagnostic catheters, PTCA guiding catheters, intravascular ultrasound (IVUS) catheters, and introducer sheaths), and plaque modification devices (coronary atherectomy, thrombectomy, embolic protection, and chronic total occlusion devices), currently derives the majority of its revenue from drug-eluting stents (DES). Because drug-eluting devices are significantly more expensive than their bare-metal predecessors, conversion to DES has contributed to the substantial growth of the US IC market over the last 2 years. As a result of continued adoption, over 99% of all stent procedures will employ a DES by 2009.

While high market saturation will prompt DES market growth to gradually subside over the next 5 years, the plaque modification segment is set to flourish. Growth will be driven by the adoption of embolic protection devices, which physicians are increasingly employing to protect against stroke during interventional procedures. The use of atherectomy devices will also increase over the next 5 years as more physicians elect to perform atherectomies prior to implanting a DES.

US Markets for Interventional Cardiology 2005 is part of MRG’s Global Interventional Cardiology series, which offers in-depth analysis of IC-related markets in the US, Europe, Japan, Latin America, and Asia Pacific. Global competitive coverage includes Abbott Vascular (ABT), Boston Scientific (BSX), Cordis (JNJ), Guidant (GDT), and Medtronic (MDT), among others. MRG has also launched the 2005 Marketfocus series, offering brand- and quarter-level coverage of the US and European markets for coronary stents, PTCA balloons, and accessory devices, as well as the US market for plaque modification.

A leading source of competitive intelligence, MRG is now the largest provider of medical device market research in the world. Located in Toronto, Canada, MRG covers global markets and has pioneered reporting of numerous emerging products.

Contact Information

Derrick Navarro

Senior Account Executive

Millennium Research Group

Contact via E-mail